Heron Therapeutics | HRTX - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 91.66M 18.01M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Emergent BioSolutions USD 182.8M 82.3M 2023-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.47M 208K 2026-06
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Merck USD 2.89B 219M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.81M 7.93M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 55.71M 4.87M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06